These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31713267)

  • 1. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
    Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
    J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.
    Saeki H; Ito K; Yokota D; Tsubouchi H
    J Am Acad Dermatol; 2022 Mar; 86(3):607-614. PubMed ID: 34710557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
    Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
    J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study.
    Saeki H; Kawashima M; Sugaya S; Oshiden K; Tsubouchi H
    J Dermatol; 2019 Aug; 46(8):672-679. PubMed ID: 34263481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.
    Saeki H; Baba N; Ito K; Yokota D; Tsubouchi H
    Br J Dermatol; 2022 Jan; 186(1):40-49. PubMed ID: 34289086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    Ma L; Zhang L; Kobayashi M; Tao X; Qian Q; Cheng H; Liu S; Zhou Y; Chen Y; Zhang J
    J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
    Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
    J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Ahmed A; Solman L; Williams HC
    Br J Dermatol; 2018 Mar; 178(3):659-662. PubMed ID: 29205284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
    J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
    Lu LC; Chao CM; Chang SP; Lan SH; Lai CC
    Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1471-1478. PubMed ID: 36210241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
    Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
    J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study.
    Saeki H; Imamura T; Yokota D; Tsubouchi H
    Dermatol Ther (Heidelb); 2022 Jul; 12(7):1589-1601. PubMed ID: 35716332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Oda M; Kabashima K; Nagata T
    J Allergy Clin Immunol; 2019 Dec; 144(6):1575-1583. PubMed ID: 31425780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
    Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
    Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.